Get the Stockscreener App
0.7615
6.88%
-0.0563
Sutro Biopharma Inc stock is traded at $0.7615, with a volume of 229.30K.
It is down -6.88% in the last 24 hours and down -7.90% over the past month.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
See More
Previous Close:
$0.8178
Open:
$0.811
24h Volume:
229.30K
Relative Volume:
0.14
Market Cap:
$70.91M
Revenue:
$153.73M
Net Income/Loss:
$-106.79M
P/E Ratio:
-0.4278
EPS:
-1.78
Net Cash Flow:
$-115.93M
1W Performance:
-0.22%
1M Performance:
-7.90%
6M Performance:
-58.84%
1Y Performance:
-80.77%
1-Day Range:
$0.7559
$0.8298
1-Week Range:
$0.7302
$0.83
52-Week Range:
$0.5231
$5.17
Sutro Biopharma Inc Stock (STRO) Company Profile
Name
Sutro Biopharma Inc
Sector
Industry
Phone
650-392-8412
Address
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare STRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
0.7615 | 70.91M | 153.73M | -106.79M | -115.93M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-14-25 | Downgrade | BofA Securities | Buy → Underperform |
| Mar-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Mar-14-25 | Downgrade | Wedbush | Outperform → Neutral |
| May-08-24 | Initiated | BofA Securities | Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-06-23 | Initiated | Oppenheimer | Outperform |
| Mar-21-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Jun-18-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-02-20 | Initiated | Jefferies | Buy |
| Jul-16-20 | Initiated | Wells Fargo | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Oct-07-19 | Initiated | BTIG Research | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Apr-29-19 | Initiated | H.C. Wainwright | Buy |
| Oct-22-18 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
| Oct-22-18 | Initiated | Wedbush | Outperform |
View All
Sutro Biopharma Inc Stock (STRO) Latest News
Sutro Biopharma (NASDAQ:STRO) Upgraded to Overweight at Piper Sandler - Defense World
Sutro Biopharma (STRO) Receives Upgrade to Overweight by Piper S - GuruFocus
Piper Sandler Upgrades Sutro Biopharma to Overweight From Neutral, $2 Price Target - MarketScreener
Sutro Biopharma (STRO) Receives Upgrade with Promising Drug Prospects | STRO Stock News - GuruFocus
Piper Sandler upgrades Sutro Biopharma stock rating on pipeline progress By Investing.com - Investing.com Canada
Bank of America Corp DE Sells 22,894 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of “Hold” by Analysts - Defense World
Piper Sandler Upgrades Sutro Biopharma (STRO) to Overweight | ST - GuruFocus
Sutro Biopharma, Inc. (NASDAQ:STRO) Stock Position Decreased by Two Sigma Investments LP - Defense World
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Millennium Management LLC - Defense World
ProShare Advisors LLC Boosts Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Nuveen Asset Management LLC Acquires 124,154 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma names Greg Chow as new CFO - Investing.com
Sutro Biopharma (STRO) Appoints New CFO Greg Chow | STRO Stock N - GuruFocus
Sutro Biopharma names Greg Chow as new CFO By Investing.com - Investing.com Canada
Sutro Biopharma Appoints Greg Chow as Chief Financial Officer - The Manila Times
Sutro Biopharma Strengthens ADC Leadership: New CFO Brings $225M Capital Raising Track Record - Stock Titan
Two Sigma Advisers LP Has $1.01 Million Stock Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Northern Trust Corp Buys 14,492 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
BNP Paribas Financial Markets Buys 68,234 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma’s SWOT analysis: stock shifts focus amid pipeline changes By Investing.com - Investing.com Nigeria
Sutro Biopharma’s SWOT analysis: stock shifts focus amid pipeline changes - Investing.com
Sutro Biopharma unveils best-in-class anti-tissue factor ADC - BioWorld MedTech
Sutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of “Hold” by Brokerages - Defense World
Sutro Biopharma (NASDAQ:STRO) Price Target Cut to $0.80 by Analysts at Bank of America - Defense World
Sutro Biopharma (STRO): Analyst Lowers Price Target by 20% | STR - GuruFocus
Bank of America Adjusts Sutro Biopharma (STRO) Price Target | ST - GuruFocus
Dimensional Fund Advisors LP Buys 156,139 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma Reports Q1 2025 Earnings and Restructuring - TipRanks
Transcript : Sutro Biopharma, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 04 - marketscreener.com
Sutro Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Barclays PLC - Defense World
Sutro Biopharma Inc Reports Q1 2025 Revenue of $17.4M, Exceeding Estimates; EPS at -$0.91, Missing Projections - GuruFocus
Sutro Biopharma First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates - NewsBreak: Local News & Alerts
Sutro Biopharma earnings missed by $0.06, revenue topped estimates - Investing.com Canada
Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights - The Manila Times
Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights | STRO Stock News - GuruFocus
Sutro Biopharma, Inc. Advances ADC Pipeline Focus with Promising Preclinical Results and Strategic Reprioritization - Nasdaq
Financial Metrics Check: Sutro Biopharma Inc (STRO)’s Ratios for Trailing Twelve Months - DWinneX
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Bought by Invesco Ltd. - Defense World
Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Globe and Mail
Sutro Biopharma (NASDAQ:STRO) Earns Neutral Rating from HC Wainwright - The AM Reporter
Sutro Biopharma to Participate in Upcoming Investor Conferences - The Manila Times
Leading ADC Developer Sutro Biopharma to Present at Citizens and BofA Healthcare Conferences in May - Stock Titan
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty - Benzinga
Sutro Biopharma (NASDAQ:STRO) Earns “Neutral” Rating from HC Wainwright - Defense World
Taking the lead: Sutro Biopharma Inc (STRO) - Sete News
Sutro Biopharma Inc Stock (STRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sutro Biopharma Inc Stock (STRO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
May 01 '25 |
Option Exercise |
0.00 |
37,849 |
0 |
133,282 |
| Srinivasan Venkatesh | CHIEF TECH OP OFFICER |
May 01 '25 |
Option Exercise |
0.00 |
2,500 |
0 |
54,580 |
| Borgman Anne Elizabeth | CHIEF MEDICAL OFFICER |
May 01 '25 |
Option Exercise |
0.00 |
69,063 |
0 |
122,161 |
| Srinivasan Venkatesh | CHIEF TECH OP OFFICER |
Apr 11 '25 |
Option Exercise |
0.00 |
21,250 |
0 |
59,683 |
| NEWELL WILLIAM J | CEO |
Mar 05 '25 |
Option Exercise |
0.00 |
18,750 |
0 |
299,239 |
| FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
Mar 05 '25 |
Option Exercise |
0.00 |
8,750 |
0 |
99,027 |
| ALBINI EDWARD C | CFO AND SECRETARY |
Mar 05 '25 |
Option Exercise |
0.00 |
8,750 |
0 |
135,675 |
| FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
Mar 04 '25 |
Option Exercise |
0.00 |
9,125 |
0 |
94,025 |
| NEWELL WILLIAM J | CEO |
Mar 04 '25 |
Option Exercise |
0.00 |
31,125 |
0 |
291,625 |
| Chung Jane | PRESIDENT AND COO |
Mar 04 '25 |
Option Exercise |
0.00 |
7,875 |
0 |
100,642 |
2.10%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):